

The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status

Man-Chiu Poon,^{1,2} Roseline d'Oiron,³ Sabin Baby,⁴ Rainer B Zotz^{5,6†} and Giovanni Di Minno⁷

¹Departments of Medicine, Pediatrics and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; ²Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center, Calgary, Alberta, Canada; ³Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles, Hôpital Bicêtre, AP-HP, and HITH, UMR_S1176, INSERM, Université Paris Saclay, Le Kremlin-Bicêtre, France; ⁴Biostatistics and Programming GD GBS, Novo Nordisk Service Center India Private Ltd, Whitefield, Bangalore, India; ⁵Institute for Laboratory Medicine, Blood Coagulation and Transfusion Medicine (LBT), Düsseldorf, Germany; ⁶Department of Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany and ⁷Department of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples, Italy

[†]*Posthumous.*

Correspondence:

M.-C. POON - mcpoon@ucalgary.ca

<https://doi.org/10.3324/haematol.2022.281973>

Supplementary data

The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status

Man-Chiu Poon,^{1,2, §} Roseline d'Oiron³, Sibin Baby⁴, Rainer B Zotz,^{5,6} Giovanni Di Minno⁷

¹*Departments of Medicine, Pediatrics and Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada;* ²*Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Centre, Calgary, Alberta, Canada;* ³*Centre de Référence de l'Hémophilie et des Maladies Hémostatiques Constitutionnelles, Hôpital Bicêtre, AP-HP, and HITH, UMR_S1176, INSERM Université Paris Saclay, Le Kremlin-Bicêtre, France;* ⁴*Biostatistics & Programming GD GBS, Novo Nordisk Service Centre India Private Ltd, Whitefield, Bangalore, India;* ⁵*Institute for Laboratory Medicine, Blood Coagulation and Transfusion Medicine (LBT), Düsseldorf, Germany;* ⁶*Department of Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University Medical Centre, Düsseldorf, Germany;* ⁷*Department of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples, Italy*

§Corresponding author:

Man-Chiu Poon mcpoon@ucalgary.ca

This file includes:

Supplementary Table S1

Supplementary Table S1. Demographics of GTR patients with a recorded change in anti-platelet antibody and/or platelet-refractoriness status (alloimmunization) following treatment including rFVIIa, platelets and antifibrinolytics alone or in combination.

	Admission	Admission date	Antibody status*	Platelet-refractoriness status†‡	Platelet-refractoriness history†‡	Treatment administered	Date treatment administered	Effectiveness to stop bleeding§
Patient: 1. Age: >18 years. Sex: M Previous treatments (at inclusion): Single donor platelets, HLA matched; Tamponade to stop bleeding; Tranexamic acid 3dd 1 g								
	1 [†]	21/05/07	HLA –	NR	NR	F7POH	Unknown	Effective
	2 [†]	Unknown	HLA +	NR	NR	POH	17/03/08	Effective
	3	17/03/08	HLA +	NR	NR	P	17/03/08	Effective
Patient: 2. Age: <18 years. Sex: M Previous treatments (at inclusion): Standard platelets; Single donor platelets; rFVIIa								
	1	20/07/08	NR	Negative	NR	F7OH	20/07/08	Effective
	2	01/12/08	Negative	Negative	NR	F7POH	01/12/08	Effective
	3	07/12/08	NR	Positive	02/12/08	F7OH	07/12/08	Effective
	4	08/01/09	NR	Positive	01/12/08	F7OH	08/01/09	Effective
	5	16/06/09	GPIIb/IIIa +	Positive	01/12/08	F7OH	16/06/09	Effective
Patient: 3. Age: <18 years. Sex: M Previous treatments (at inclusion): Standard platelets; RBCs; Antifibrinolytic tranexamic acid; rFVIIa								
	1	01/01/04	Negative	Negative	NR	POH	01/01/04	Effective
	2	07/01/04	Negative	Negative	NR	P	07/01/04	Effective
	3	21/07/04	Negative	Negative	NR	OH	21/07/04	Effective
	4	12/10/07	Negative	Negative	NR	P	12/10/07	Effective
	5	04/04/09	Negative	Negative	NR	P	04/04/09	Effective
	6	28/04/09	Negative	Negative	NR	F7	28/04/09	Effective
	7	22/09/09	Positive	Positive	01/07/09	F7OH	22/09/09	Effective
	8	05/10/09	Positive	Positive	01/07/09	F7POH	07/10/09	Effective
	9	25/02/10	Positive	Positive	01/09/09	F7POH	25/02/10	Partially effective
	10	11/08/10	Positive	Positive	01/09/09	F7	11/08/10	Partially effective
	11	02/12/10	Positive	Positive	01/07/09	F7OH	02/12/10	Partially effective
Patient: 4. Age <18 years. Sex: M Previous treatments (at inclusion): Standard platelets; RBCs; Steroids								
	1	23/04/09	Negative	Negative	NR	OH	23/04/09	Effective
	2	29/05/09	NR	Negative	NR	POH	30/05/09	Effective
	3	03/04/10	NR	Positive	03/04/10	P	03/04/10	Ineffective
Patient: 5. Age: <18 years. Sex: F Previous treatments (at inclusion): Standard platelets; RBCs; rFVIIa; DDAVP; FFP; CP								
	1	21/11/08	NR	Positive	NR	POH	21/11/08	Partially effective
	2	29/11/08	NR	NR	NR	POH	29/11/08	Partially effective
	3	13/12/08	NR	NR	NR	POH	13/12/08	Partially effective
	4	14/03/09	NR	NR	NR	POH	14/03/09	Partially effective
	5	09/04/09	Positive	Positive	01/12/08	POH	25/03/09	Partially effective
	6	12/04/09	Positive	Positive	01/12/08	POH	04/04/09	Partially effective
	7	13/04/09	Positive	Positive	01/12/08	POH	13/04/09	Partially effective
	8	17/04/09	Positive	Positive	01/12/08	P	17/04/09	Partially effective
	9	18/04/09	Positive	Positive	01/12/08	POH	18/04/09	Partially effective
	10	29/04/09	Positive	Positive	01/12/08	POH	26/04/09	Partially effective
	11	08/06/09	Positive	Positive	01/03/08	POH	08/06/09	Partially effective
	12	25/06/09	Positive	Positive	01/12/08	F7POH	25/06/09	Effective
	13	28/08/09	Positive	Positive	NR	POH	27/08/09	Effective
	14	13/09/09	Positive	Positive	NR	POH	13/09/09	Effective
	15	14/09/09	Positive	Positive	NR	POH	14/09/09	Effective
	16	28/10/09	Negative	Positive	01/03/08	POH	28/10/09	Effective
	17	03/11/09	Positive	Positive	01/03/08	POH	03/11/09	Effective
	18	10/11/09	Positive	Positive	01/03/08	POH	10/11/09	Partially effective
	19	12/11/09	Positive	Positive	01/03/08	POH	12/11/09	Partially effective
	20	24/12/09	Positive	Positive	01/03/08	POH	24/12/09	Partially effective
	21	03/01/10	Positive	Positive	01/03/08	POH	03/01/10	Partially effective
	22	09/03/10	NR	Positive	NR	POH	09/03/10	Partially effective
	23	18/03/10	NR	Positive	NR	POH	18/03/10	Effective
	24	27/03/10	NR	Positive	NR	POH	27/03/10	Effective
	25	19/07/10	NR	Positive	NR	POH	19/07/10	Effective
	26	17/08/10	NR	NR	NR	OH	17/08/10	Effective

The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status

Supplementary data

27	28/08/10	NR	NR	NR	POH	28/08/10	Effective
28	23/09/10	NR	NR	NR	POH	23/09/10	Partially effective
29	27/10/10	NR	NR	NR	POH	27/10/10	Effective
30	09/11/10	NR	NR	NR	POH	09/11/10	Effective
31	29/11/10	NR	NR	NR	P	29/11/10	Effective
32	06/12/10	NR	NR	NR	P	06/12/10	Ineffective
33	12/12/10	NR	NR	NR	P	12/12/10	Partially effective
34	13/01/11	NR	NR	NR	P	13/01/11	Partially effective
35	09/02/11	NR	NR	NR	P	09/02/11	Effective
36	24/02/11	NR	NR	NR	P	24/02/11	Effective
37	25/02/11	NR	Positive	NR	P	25/02/11	Partially effective
38	02/03/11	NR	NR	NR	P	02/03/11	Partially effective
39	03/03/11	NR	Positive	NR	POH	03/03/11	Effective
40	10/03/11	NR	Positive	NR	P	10/03/11	Effective
41	14/03/11	NR	NR	NR	P	14/03/11	Partially effective
42	30/03/11	NR	Positive	NR	P	30/03/11	Partially effective
43	31/03/11	NR	NR	NR	P	31/03/11	Partially effective
44	03/04/11	NR	Positive	NR	P	03/04/11	Effective
45	21/04/11	NR	Positive	NR	POH	21/04/11	Effective
46	05/05/11	NR	NR	NR	P	05/05/11	Partially effective
47	16/05/11	NR	Positive	NR	OH	NR	Effective
48	20/06/11	NR	NR	NR	OH	NR	Effective
49	17/07/11	NR	NR	NR	P	17/07/11	Partially effective
50	30/07/11	NR	Negative	NR	P	30/07/11	Effective
51	08/08/11	NR	Positive	NR	POH	08/08/11	Effective
52	14/08/11	NR	Negative	NR	POH	14/08/11	Effective
53	17/08/11	NR	Negative	NR	POH	17/08/11	Effective
54	23/09/11	NR	Negative	NR	POH	23/09/11	Effective
Unknown ^l	Unknown	NR	NR	NR	POH	Unknown	Effective

*Date of antibody status testing recorded for Patient 1, admission 1 (05/11/2007); NR for Patients 2–5.

†Platelet-refractoriness was defined as: bleeding during surgery despite an adequate amount (as determined by the treating clinician) of platelet infusion, and/or persistence of bleeding despite an adequate amount (as determined by the treating clinician) of platelet infusion, and/or rebleeding within 24 h despite an adequate amount (as determined by the treating clinician) of platelet infusion.^{1, 2}

‡Patients previously recorded as refractory for platelets are considered positive unless a further instance produces a negative result.

§Effectiveness of treatment during surgery was defined as: effective, normal hemostasis; partially effective, mild bleeding tendency; ineffective, excessive bleeding tendency. Effectiveness of treatment during a bleeding event was defined as: effective, bleeding stopped and hemostasis achieved for ≥6 h; partially effective, bleeding decreased substantially but continued; ineffective, bleeding unchanged or worsened following treatment.^{1, 2}

^lThe admission and/or treatment dates could not be verified.

CP, cryoprecipitate; DDAVP, desmopressin; dd, daily doses; F7, recombinant activated factor seven; FFP, fresh frozen plasma; GPIIb/IIIa, glycoprotein IIb/IIIa; GPIIb/IIIa +, GPIIb/IIIa positive; GTR, Glanzmann Thrombasthenia Registry; HLA, human leukocyte antigen; HLA –, HLA negative; HLA +, HLA positive; NR, not reported; OH, other hemostatic treatment (mostly antifibrinolytics); P, platelets; POH, platelets and other hemostatic treatment (most antifibrinolytics); RBCs, red blood cells; rFVIIa, recombinant activated factor VII.

References

1. Di Minno G, Zotz RB, d'Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. *Haematologica*. 2015;100(8):1031-1037.
2. Poon MC, d'Oiron R, Zotz RB, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. *Haematologica*. 2015;100(8):1038-1044.